nach oben

Arthritis Research & Therapy

Erschienen in:

01.05.2002 | Review

Endothelial activation: intracellular signaling pathways

verfasst von: Jordan S Pober

Erschienen in: Arthritis Research & Therapy | Sonderheft 3/2002

Einloggen, um Zugang zu erhalten

Chapter summary

Tumor necrosis factor (TNF) is the prototypic proinflammatory cytokine and endothelial cells are the principal cellular targets of its actions. Here I review the responses of endothelial cells to TNF, with emphasis on the induction of endothelial leukocyte adhesion molecules. I focus on the biochemistry and cell biology of signal transduction in TNF-treated endothelial cells that lead to the expression of adhesion molecules.

Etazioni A, Doerschuk CM, Harlan JM: Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood. 1999, 94: 3281-3288.

Cohnheim J: Lectures in General Pathology. Translated by Al McKee from the 2nd German edn. London: New Sydenham Society 1989

Robbins SL, Angell M, Kumar V, Eds: Chapter 2: Inflammation and repair. In Basic Pathology, 4th edn. Philadelphia: WB Saunders 1981, 28-61

Tonnesen MG, Smedly LA, Henson PM: Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro. J Clin Invest. 1984, 74: 1581-1592.PubMedPubMedCentralCrossRef

Bjork J, Hugli TE, Smedegard G: Microvascular effects of anaphylatoxins C3a and C5a. J Immunol. 1985, 134: 1115-1119.PubMed

Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA: Interleukin-1 acts on cultured human vascular endothelial cells to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985, 76: 2003-2011.PubMedPubMedCentralCrossRef

Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physiol Rev. 1990, 70: 427-451.PubMed

Butcher EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991, 67: 1033-1036.PubMedCrossRef

Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994, 76: 301-314.PubMedCrossRef

10.

Petzelbauer P, Bender J, Wilson J, Pober JS: Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol. 1993, 151: 5062-5072.PubMed

11.

Petzelbauer P, Pober JS, Keh A, Braverman IM: Inducibility and expression of microvascular endothelial adhesion molecules in lesional, perilesional, and uninvolved skin of psoriatic patients. J Invest Dermatol. 1994, 103: 300-305.PubMedCrossRef

12.

Briscoe DM, Cotran RS, Pober JS: Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol. 1992, 149: 2954-2960.PubMed

13.

Doukas J, Pober JS: IFN-gamma enhances endothelial activation induced by tumor necrosis factor but not IL-1. J Immunol. 1990, 145: 1727-1733.PubMed

14.

Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO: Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol. 1991, 146: 592-598.PubMed

15.

Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A: P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature. 1997, 385: 81-83. 10.1038/385081a0.PubMedCrossRef

16.

Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L, Kollias G: Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm. 1995, 47: 27-38.PubMed

17.

Feldmann M, Maini RN, Bondeson J, Taylor P, Foxwell BM, Brennan FM: Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol. 2001, 490: 119-127.PubMedCrossRef

18.

Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995, 9: 899-909.PubMed

19.

Slowik MR, De Luca LG, Fiers W, Pober JS: Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol. 1993, 143: 1724-1730.PubMedPubMedCentral

20.

Ledgerwood EC, Pober JS, Bradley JR: Recent advances in the molecular basis of TNF signal transduction. Lab Invest. 1999, 79: 1041-1050.PubMed

21.

Madge LA, Pober JS: TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001, 70: 317-325. 10.1006/exmp.2001.2368.PubMedCrossRef

22.

Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein TRADD signals cell death and NF- kappa B activation. Cell. 1995, 81: 495-504.PubMedCrossRef

23.

Telliez JB, Xu GY, Woronicz JD, Hsu S, Wu JL, Lin L, Sukits SF, Powers R, Lin LL: Mutational analysis and NMR studies of the death domain of the tumor necrosis factor receptor-1. J Mol Biol. 2000, 300: 1323-1333. 10.1006/jmbi.2000.3899.PubMedCrossRef

24.

Sukits SF, Lin LL, Hsu S, Malakian K, Powers R, Xu GY: Solution structure of the tumor necrosis factor receptor-1 death domain. J Mol Biol. 2001, 310: 895-906. 10.1006/jmbi.2001.4790.PubMedCrossRef

25.

Jiang Y, Woronicz JD, Liu W, Goeddel DV: Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science. 1999, 283: 543-546. 10.1126/science.283.5401.543.PubMedCrossRef

26.

Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996, 84: 299-308.PubMedCrossRef

27.

Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996, 4: 387-396.PubMedCrossRef

28.

Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P: The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998, 8: 297-303.PubMedCrossRef

29.

Park YC, Ye H, Hsia C, Segal D, Rich RL, Liou H-C, Myszka DG, Wu H: A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell. 2000, 101: 777-787.PubMedCrossRef

30.

Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A. 1999, 96: 11364-11369. 10.1073/pnas.96.20.11364.PubMedPubMedCentralCrossRef

31.

Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW: Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997, 7: 715-725.PubMedCrossRef

32.

Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, Yeh WC, Nakano H: Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem. 2001, 276: 36530-36534. 10.1074/jbc.M104837200.PubMedCrossRef

33.

Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z: The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000, 12: 419-429.PubMedCrossRef

34.

Xia Y, Makris C, Su B, Li E, Yang J, Nemerow GR, Karin M: MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A. 2000, 97: 5243-5248. 10.1073/pnas.97.10.5243.PubMedPubMedCentralCrossRef

35.

Yang J, Ling Y, Guo Z, Cheng J, Huang J, Deng L, Liao W, Chen Z, Liu Z-g, Su B: The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol. 2001, 2: 620-624. 10.1038/89769.PubMedCrossRef

36.

Karin M: The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem. 1999, 274: 27339-27342. 10.1074/jbc.274.39.27339.PubMedCrossRef

37.

Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV: Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-b-deficient mice. Immunity. 1999, 10: 421-429.PubMedCrossRef

38.

Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M: The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 1999, 189: 1839-1845. 10.1084/jem.189.11.1839.PubMedPubMedCentralCrossRef

39.

Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ, Mak TW: Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 2000, 14: 854-862.PubMedPubMedCentral

40.

Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996, 14: 649-683. 10.1146/annurev.immunol.14.1.649.PubMedCrossRef

41.

Johnson DR, Douglas I, Jahnke A, Ghosh S, Pober JS: A sustained reduction in IkappaB-beta may contribute to persistent NF- kappaB activation in human endothelial cells. J Biol Chem. 1996, 271: 16317-16322. 10.1074/jbc.271.27.16317.PubMedCrossRef

42.

Spiecker M, Darius H, Liao JK: A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol. 2000, 164: 3316-3322.PubMedCrossRef

43.

Lewis H, Kaszubska W, DeLamarter JF, Whelan J: Cooperativity between two NF-kappa B complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol Cell Biol. 1994, 14: 5701-5709.PubMedPubMedCentralCrossRef

44.

Schindler U, Baichwal VR: Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol. 1994, 14: 5820-5831.PubMedPubMedCentralCrossRef

45.

Whitley MZ, Thanos D, Read MA, Maniatis T, Collins T: A striking similarity in the organization of the E-selectin and beta inter-feron gene promoters. Mol Cell Biol. 1994, 14: 6464-6475.PubMedPubMedCentralCrossRef

46.

Shu HB, Agranoff AB, Nabel EG, Leung K, Duckett CS, Neish AS, Collins T, Nabel GJ: Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells. Mol Cell Biol. 1993, 13: 6283-6289.PubMedPubMedCentralCrossRef

47.

Ahmad M, Marui N, Alexander RW, Medford RM: Cell type-specific transactivation of the VCAM-1 promoter through an NF-kappa B enhancer motif. J Biol Chem. 1995, 270: 8976-8983. 10.1074/jbc.270.15.8976.PubMedCrossRef

48.

Parry GC, Mackman N: A set of inducible genes expressed by activated human monocytic and endothelial cells contain kappa B-like sites that specifically bind c-Rel-p65 het-erodimers. J Biol Chem. 1994, 269: 20823-20825.PubMed

49.

Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001, 11: 372-377. 10.1016/S0962-8924(01)02064-5.PubMedCrossRef

50.

De Luca LG, Johnson DR, Whitley MZ, Collins T, Pober JS: cAMP and tumor necrosis factor competitively regulate transcriptional activation through and nuclear factor binding to the cAMP-responsive element/activating transcription factor element of the endothelial leukocyte adhesion molecule-1 (E-selectin) promoter. J Biol Chem. 1994, 269: 19193-19196.PubMed

51.

Min W, Pober JS: TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways. J Immunol. 1997, 159: 3508-3518.PubMed

52.

Reimold AM, Grusby MJ, Kosaras B, Fries JW, Mori R, Maniwa S, Clauss IM, Collins T, Sidman RL, Glimcher MJ, Glimcher LH: Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature. 1996, 379: 262-265. 10.1038/379262a0.PubMedCrossRef

53.

Stade BG, Messer G, Riethmuller G, Johnson JP: Structural characteristics of the 5' region of the human ICAM-1 gene. Immunobiology. 1990, 182: 79-87.PubMedCrossRef

54.

Cybulsky MI, Allan-Motamed M, Collins T: Structure of the murine VCAM1 gene. Genomics. 1993, 18: 387-391. 10.1006/geno.1993.1480.PubMedCrossRef

55.

Ahmad M, Theofanidis P, Medford RM: Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-. J Biol Chem. 1998, 273: 4616-4621. 10.1074/jbc.273.8.4616.PubMedCrossRef

56.

Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A. 1997, 94: 2927-2932. 10.1073/pnas.94.7.2927.PubMedPubMedCentralCrossRef

57.

Karmann K, Min W, Fanslow WC, Pober JS: Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J Exp Med. 1996, 184: 173-182.PubMedCrossRef

58.

Duckett CS, Thompson CB: CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 1997, 11: 2810-2821.PubMedPubMedCentralCrossRef

59.

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1016/S0039-6028(97)00913-8.PubMedCrossRef

60.

Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Annu Rev Physiol. 1998, 60: 643-665. 10.1146/annurev.physiol.60.1.643.PubMedCrossRef

61.

Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ, Vadas MA: Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A. 1998, 95: 14196-14201. 10.1073/pnas.95.24.14196.PubMedPubMedCentralCrossRef

62.

Xu XS, Vanderziel C, Bennett CF, Monia BP: A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J Biol Chem. 1998, 273: 33230-33238. 10.1074/jbc.273.50.33230.PubMedCrossRef

63.

Madge LA, Pober JS: A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem. 2000, 275: 15458-15465. 10.1074/jbc.M001237200.PubMedCrossRef

64.

Slowik MR, De Luca LG, Min W, Pober JS: Ceramide is not a signal for tumor necrosis factor-induced gene expression but does cause programmed cell death in human vascular endothelial cells. Circ Res. 1996, 79: 736-747.PubMedCrossRef

65.

Bradley JR, Thiru S, Pober JS: Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol. 1994, 146: 27-32.

66.

Gaeta ML, Johnson DR, Kluger MS, Pober JS: The death domain of tumor necrosis factor receptor 1 is necessary but not sufficient for Golgi retention of the receptor and mediates receptor desensitization. Lab Invest. 2000, 80: 1185-1194.PubMedCrossRef

67.

Feng X, Gaeta ML, Madge LA, Yang JH, Bradley JR, Pober JS: Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J Biol Chem. 2001, 276: 8341-8349. 10.1074/jbc.M007116200.PubMedCrossRef

68.

Tartaglia LA, Pennica D, Goeddel DV: Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem. 1993, 268: 18542-18548.PubMed

69.

Ledgerwood EC, Prins JB, Bright NA, Johnson DR, Wolfreys K, Pober JS, O'Rahilly S, Bradley JR: Tumor necrosis factor is delivered to mitochondria where a tumor necrosis factor-binding protein is localized. Lab Invest. 1998, 78: 1583-1589.PubMed

70.

Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR: Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest. 2001, 81: 1503-1515.PubMedCrossRef

71.

Cottin V, Van Linden A, Riches DW: Phosphorylation of tumor necrosis factor receptor CD120a (p55) by p42(MAPK/ERK2) induces changes in its subcellular localization. J Biol Chem. 1999, 274: 32975-32987. 10.1074/jbc.274.46.32975.PubMedCrossRef

72.

Madge LA, Sierra-Honigmann MR, Pober JS: Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1). A nonpharmacological explanation for inhibition of TNF-mediated activation. J Biol Chem. 1999, 274: 13643-13649. 10.1074/jbc.274.19.13643.PubMedCrossRef

73.

Wallach D, Engelmann H, Nophar Y, Aderka D, Kemper O, Hornik V, Holtmann H, Brakebusch C: Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991, 35: 51-57.PubMed

74.

Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL: TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000, 12: 479-486. 10.1016/S0952-7915(00)00124-2.PubMedCrossRef

75.

Jones SJ, Ledgerwood EC, Prins JB, Savidge J, Johnson DR, Pober JS, Bradley JR: TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol. 1999, 162: 1042-1048.PubMed

76.

Bradley JR, Johnson DR, Pober JS: Four different classes of inhibitors of receptor-mediated endocytosis decrease TNF-induced gene expression in human endothelial cells. J Immunol. 1993, 150: 5544-5555.PubMed

77.

Schutze S, Machleidt T, Adam D, Schwandner R, Wiegmann K, Kruse ML, Heinrich M, Wickel M, Kronke M: Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem. 1999, 274: 10203-10212. 10.1074/jbc.274.15.10203.PubMedCrossRef

78.

Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000, 1: 31-39. 10.1038/35036052.PubMedCrossRef

79.

Galbiati F, Razani B, Lisanti MP: Emerging themes in lipid rafts and caveolae. Cell. 2001, 106: 403-411.PubMedCrossRef

80.

Schlegel A, Lisanti MP: The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction. Cytokine Growth Factor Rev. 2001, 12: 41-51. 10.1016/S1359-6101(00)00022-8.PubMedCrossRef

Titel: Endothelial activation: intracellular signaling pathways
verfasst von: Jordan S Pober
Publikationsdatum: 01.05.2002
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe Sonderheft 3/2002
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar576

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endothelial activation: intracellular signaling pathways

Chapter summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chapter summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2002

Epidemiology and genetics of rheumatoid arthritis

Studies of T-cell activation in chronic inflammation

Complement and systemic lupus erythematosus

Insights into integrin-ligand binding and activation from the first crystal structure

Matrix metalloproteinases in arthritic disease

Interactions between leukocytes and endothelial cells in gout: lessons from a self-limiting inflammatory response

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin